ImmunityBio (IBRX) News Today $2.53 -0.15 (-5.60%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.54 +0.01 (+0.40%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Woodline Partners LP Buys 3,002,622 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)Woodline Partners LP raised its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 682.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,442,440 shares of the company's stock after purchasing an additional 3,002,622 sharesMay 25 at 4:41 AM | marketbeat.com10 Firms Drenched in Red TodayMay 23 at 8:36 AM | insidermonkey.comImmunityBio, Inc. (NASDAQ:IBRX) Shares Bought by Rafferty Asset Management LLCRafferty Asset Management LLC raised its position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 20.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 549,905 shares of the company's stoMay 23 at 4:37 AM | marketbeat.comPiper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PTMay 22 at 6:37 PM | msn.comImmunityBio (NASDAQ:IBRX) Rating Increased to Overweight at Piper SandlerPiper Sandler upgraded ImmunityBio from a "neutral" rating to an "overweight" rating and set a $5.00 target price on the stock in a research note on Tuesday.May 22 at 8:12 AM | marketbeat.comJim Cramer’s Recent Thoughts on These 15 StocksMay 22 at 12:31 AM | insidermonkey.comJim Cramer Notes ImmunityBio (IBRX) Has “Been Losing Money Forever”May 20, 2025 | msn.comImmunityBio upgraded to Overweight at Piper Sandler on Anktiva successMay 20, 2025 | msn.comWhy ImmunityBio, Inc. (IBRX) Surged Last WeekMay 20, 2025 | msn.comTang Capital Management LLC Makes New $7.20 Million Investment in ImmunityBio, Inc. (NASDAQ:IBRX)Tang Capital Management LLC bought a new position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,814,192 shares of the company's stock, valued at approximately $7,204,000.May 20, 2025 | marketbeat.comImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The UpsideMay 19, 2025 | msn.comQ2 Earnings Forecast for ImmunityBio Issued By HC WainwrightMay 17, 2025 | americanbankingnews.comEarnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00May 14, 2025 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Stock Price Up 15.1% - Still a Buy?ImmunityBio (NASDAQ:IBRX) Trading 15.1% Higher - Time to Buy?May 14, 2025 | marketbeat.comImmunityBio's (IBRX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of ImmunityBio in a research note on Monday.May 14, 2025 | marketbeat.comD. Boral Capital Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX)D. Boral Capital reissued a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Monday.May 14, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Issues Earnings ResultsImmunityBio (NASDAQ:IBRX - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.03).May 14, 2025 | marketbeat.comWhy These 10 Stocks Soared by Double Digits TodayMay 14, 2025 | insidermonkey.comWhy ImmunityBio, Inc. (IBRX) Soared TodayMay 13, 2025 | msn.comImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-codeMay 12, 2025 | businesswire.comFirst Trust Advisors LP Has $428,000 Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)First Trust Advisors LP cut its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 77.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 167,200 shares of the company's stock after selling 589,609 shares during the peMay 12, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Reaches New 12-Month Low - What's Next?ImmunityBio (NASDAQ:IBRX) Sets New 1-Year Low - What's Next?May 8, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Down - What's Next?ImmunityBio (NASDAQ:IBRX) Shares Gap Down - Time to Sell?May 7, 2025 | marketbeat.comImmunityBio Slides Following FDA Refusal-to-File LetterMay 6, 2025 | marketwatch.comImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s PositiveMay 6, 2025 | msn.comImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLAMay 5, 2025 | seekingalpha.comImmunityBio Requests Meeting With FDA Over Rejected Bladder Treatment ApplicationMay 5, 2025 | marketwatch.comImmunityBio stock sinks after FDA issues RTF letterMay 5, 2025 | in.investing.comImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025May 5, 2025 | businesswire.comMarshall Wace LLP Makes New $615,000 Investment in ImmunityBio, Inc. (NASDAQ:IBRX)Marshall Wace LLP bought a new stake in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 240,311 shares of the company's stock, valued at approximately $615,000. SMay 5, 2025 | marketbeat.comImmunityBio (IBRX) to Release Quarterly Earnings on ThursdayImmunityBio (NASDAQ:IBRX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-immunitybio-inc-stock/)May 3, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Down 4.4% - Time to Sell?ImmunityBio (NASDAQ:IBRX) Shares Down 4.4% - Here's WhyMay 1, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of ImmunityBio in a research note on Monday.April 30, 2025 | marketbeat.comImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term BullishApril 29, 2025 | seekingalpha.comGhisallo Capital Management LLC Invests $1.28 Million in ImmunityBio, Inc. (NASDAQ:IBRX)Ghisallo Capital Management LLC bought a new stake in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 500,000 shares of the company's stock, valued at apprApril 28, 2025 | marketbeat.comImmunityBio, Inc. (NASDAQ:IBRX) Shares Bought by LPL Financial LLCLPL Financial LLC grew its position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 67.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 257,449 shares of the company's stock after acquiring an additional 103,495 shares during the periApril 26, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Receives Buy Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and set a $30.00 target price on shares of ImmunityBio in a report on Wednesday.April 25, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 99,048 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)JPMorgan Chase & Co. lowered its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 8.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,041,863 shares of the company's stock after selling 99,048 sharesApril 25, 2025 | marketbeat.comImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual MeetingApril 21, 2025 | businesswire.comFranklin Resources Inc. Lowers Position in ImmunityBio, Inc. (NASDAQ:IBRX)Franklin Resources Inc. decreased its stake in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 54.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 88,686 shares of the company's stApril 21, 2025 | marketbeat.comQ1 Earnings Forecast for ImmunityBio Issued By HC WainwrightImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for ImmunityBio in a research report issued on Wednesday, April 16th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings perApril 20, 2025 | marketbeat.comAltium Capital Management LLC Takes $2.71 Million Position in ImmunityBio, Inc. (NASDAQ:IBRX)Altium Capital Management LLC acquired a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,060,000 shares of the company's stock, valued at approximately $2,714,000. AltiumApril 20, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Down 6.3% - Should You Sell?ImmunityBio (NASDAQ:IBRX) Shares Down 6.3% - What's Next?April 18, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of ImmunityBio in a research note on Wednesday.April 18, 2025 | marketbeat.comImmunityBio sees Q1 sales surge, submits FDA applicationsApril 18, 2025 | uk.investing.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's WhyImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's WhyApril 17, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Up 7.8% - Here's What HappenedImmunityBio (NASDAQ:IBRX) Trading 7.8% Higher - Should You Buy?April 16, 2025 | marketbeat.comWhy ImmunityBio Inc. (IBRX) Skyrocketed On Monday?April 15, 2025 | msn.comImmunityBio, Inc. (NASDAQ:IBRX) Stake Increased by Vanguard Group Inc.Vanguard Group Inc. raised its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 2.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,328,229 shares of the company's stock after acquiring an additiApril 14, 2025 | marketbeat.comImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and set a $30.00 price target on shares of ImmunityBio in a report on Wednesday.April 11, 2025 | marketbeat.com Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IBRX Media Mentions By Week IBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.290.75▲Average Medical News Sentiment IBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼124▲IBRX Articles Average Week Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ASND News QGEN News ROIV News RVMD News ELAN News BPMC News BBIO News VRNA News TLX News GRFS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IBRX Stock Free IBRX Stock Alerts